MDT-AP-2021
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 24
- os_event
- false
- age_years
- 14.76
- sex
- F
- new_clusters
- C4
- umap1_2d
- 4.244508672
- umap2_2d
- 4.715011423
- umap1_3d
- 1.103134728
- umap2_3d
- -0.6645001
- umap3_3d
- -2.584770762
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.690
- INTERFERON_GAMMA_RESPONSE+0.630
- ANGIOGENESIS+0.600
- IL6_JAK_STAT3_SIGNALING+0.600
- INFLAMMATORY_RESPONSE+0.570
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- ALLOGRAFT_REJECTION+0.550
- COAGULATION+0.500
- COMPLEMENT+0.490
- TNFA_SIGNALING_VIA_NFKB+0.490
Top 10 suppressed
- E2F_TARGETS-0.530
- G2M_CHECKPOINT-0.500
- MYC_TARGETS_V2-0.410
- MITOTIC_SPINDLE-0.390
- MYC_TARGETS_V1-0.370
- SPERMATOGENESIS-0.200
- KRAS_SIGNALING_DN-0.090
- HEDGEHOG_SIGNALING-0.050
- PEROXISOME+0.010
- UNFOLDED_PROTEIN_RESPONSE+0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_M4TTKPNR | pilocytic astrocytoma | — | 0.944 |
| 2 | BS_HC5M8JTC | low-grade glioma | — | 0.943 |
| 3 | BS_55JW3HFM | Ganglioglioma | — | 0.933 |
| 4 | BS_769BDPDB | pilocytic astrocytoma | — | 0.930 |
| 5 | SRR8518191 | — | D | 0.928 |
| 6 | TCGA-CV-7433-01A-11R-2132-07 | — | — | 0.926 |
| 7 | BS_Z0AVVB1V | pilocytic astrocytoma | — | 0.925 |
| 8 | BS_HX0S30NE | pilocytic astrocytoma | — | 0.925 |
| 9 | BS_MF9X3PKH | low-grade glioma | — | 0.922 |
| 10 | BS_3W07B2TG | subependymal giant cell astrocytoma(SEGA) | — | 0.922 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.690 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.630 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.600 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.600 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.570 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.550 | Idelalisib | — uncovered |
| COAGULATION | 0.500 | Binimetinib | — uncovered |
| COMPLEMENT | 0.490 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.490 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.440 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.430 | Idelalisib | — uncovered |
| APOPTOSIS | 0.410 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.370 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.330 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| HYPOXIA | 0.320 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.310 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |